{
  "docId": "019de070-f8c0-72fa-b47b-4b134ca99d3b",
  "docSlug": "4fd785179c9b78e08eb8c823d8e306e6",
  "documentTitle": "argenx SE | Results Presentation Deck | 24 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 24,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a funnel-like visual to represent growth in indications, with color-coded dots representing therapeutic areas (Neuro, Heme, Skin, Kidney).",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-f8c0-72fa-b47b-4b134ca99d3b/22",
  "deckHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b",
  "deckJsonHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b.json",
  "deckAnchorHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.92,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "Roadmap of clinical indications",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11ed97e5-765f-4acc-bc04-ca427312098e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.7,
        "x": 0.3,
        "y": 0
      },
      "kind": "image",
      "text": "People icons representing patient population growth",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f45f72c-b107-47b3-b7f3-611af3858ffd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.04,
        "y": 0.86
      },
      "kind": "legend",
      "text": "Key: NEURO, HEME, SKIN, KIDNEY",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14e87385-597e-40f7-88e6-136db44b6356",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.12,
        "y": 0.68
      },
      "kind": "other",
      "text": "Clinical study logos (adapt, advance, address, adhere)",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96edeed4-6372-4722-a93c-77d352d47ce8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "MYASTHENIA GRAVIS Is Just The Beginning",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce066da5-cc50-4ad5-8eb6-c2b674d002e5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "roadmap",
      "slug": null,
      "matchId": "c6241dcb-645f-4fc2-a586-517eecba90f4",
      "evidence": "Visual timeline of clinical indications and studies",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 22,
      "from": 13,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "75721239-1041-4fe6-8eab-446d817772cd",
      "evidence": "Slides 13 and 22 discuss the need for new therapies and the potential of Efgartigimod.",
      "position": 0,
      "objective": "Highlighting the cost of inaction for MG patients.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}